Compare RGP & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | KRRO |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 150.0M |
| IPO Year | 2000 | 2019 |
| Metric | RGP | KRRO |
|---|---|---|
| Price | $4.41 | $11.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $7.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 251.5K | 76.2K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $551,331,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $3.06 | $5.20 |
| 52 Week High | $6.07 | $55.89 |
| Indicator | RGP | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 39.82 |
| Support Level | $4.22 | $10.81 |
| Resistance Level | $4.86 | $14.52 |
| Average True Range (ATR) | 0.18 | 0.85 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 83.97 | 2.57 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.